Profile
Sector:
HealthcareCountry:
United StatesIPO:
07 January 2014Next earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 02 Jul 2024 22:35:54 GMTDividend
Analysts recommendations
Institutional Ownership
ITCI Latest News
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Caplyta (lumateperone) shows significant promise as an adjunctive treatment for Major Depressive Disorder. Caplyta's unique pharmacological profile targeting serotonin, dopamine, and glutamate pathways sets it apart in the saturated MDD market. Intra-Cellular's financial stability is supported by strong sales growth and sufficient cash reserves to sustain operations until 2027.
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock?
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today highlights data presentations at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting being held in Miami, May 28 - 31, 2024.
Intra-Cellular (ITCI) surges 23% following successful completion of late-stage study assessing lumateperone 42 mg as a supplemental treatment to antidepressants for MDD.
Intra-Cellular (ITCI) experienced a significant increase in its stock price in the last trading session, with higher than usual trading volume. The recent changes in earnings estimates suggest that there may be additional price growth in the short term.
Intra-Cellular (ITCI) reports mixed fourth-quarter 2023 results despite Caplyta sales rising year over year on the back of increasing prescription trends.
Intra-Cellular's share price has increased by 450% over a five-year period and over 50% in the past year. The company's success is attributed to its approved drug, Caplyta, which has driven significant revenue growth. Intra-Cellular is running Phase 3 studies to expand Caplyta's label into major depressive disorder, presenting a potential future growth opportunity.
- 1(current)
What type of business is Intra-Cellular Therapies?
Intra-Cellular Therapies, Inc. is an American biopharmaceutical company. It has been in operation since 2001 and was officially registered in 2013 in the state of Delaware. The headquarters are located in New York. The company focuses on the development of small molecule drugs for the treatment of neuropsychiatric and neurological disorders. The drug candidate CAPLYTA has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults and is currently entering the commercialization phase. The drug candidate Lumateperone is intended for the treatment of depression associated with bipolar disorders, as well as for the treatment of agitation in patients with dementia, including Alzheimer's disease.
What sector is Intra-Cellular Therapies in?
Intra-Cellular Therapies is in the Healthcare sector
What industry is Intra-Cellular Therapies in?
Intra-Cellular Therapies is in the Drug Manufacturers - Specialty & Generic industry
What country is Intra-Cellular Therapies from?
Intra-Cellular Therapies is headquartered in United States
When did Intra-Cellular Therapies go public?
Intra-Cellular Therapies initial public offering (IPO) was on 07 January 2014
What is Intra-Cellular Therapies website?
https://www.intracellulartherapies.com
Is Intra-Cellular Therapies in the S&P 500?
No, Intra-Cellular Therapies is not included in the S&P 500 index
Is Intra-Cellular Therapies in the NASDAQ 100?
No, Intra-Cellular Therapies is not included in the NASDAQ 100 index
Is Intra-Cellular Therapies in the Dow Jones?
No, Intra-Cellular Therapies is not included in the Dow Jones index
When does Intra-Cellular Therapies report earnings?
The next expected earnings date for Intra-Cellular Therapies is 02 August 2024